Explore our certified R&D modules spanning high-throughput botanical screening, validated pharmacokinetics, preclinical toxicological profiling, and regulated clinical development.
Systematic in vivo safety and efficacy validation in verified disease animal models to support rapid dossier filings.
Configure Protocol
GCP-compliant human trials from first-in-human Phase I to post-marketing Phase IV efficacy evaluations.
Explore Phase Design
Multi-geographical fingerprinting to locate highest metabolite density windows across diverse cultivation hubs.
Request Origin Data
Targeted bioactivity assays, molecular target binding, and enzyme kinetics on validated mammalian cell lines.
View Assay Panels
Full ICH Q2(R1) method development, HPLC/HPTLC/GC-MS fingerprinting, and quantitative monographs.
Method Development
Metabolomic isolation and characterization of bioactive flavonoids, terpenes, alkaloids, and polysaccharides.
Screen Molecules
Commercial encapsulation, tableting, micro-granules, and oral liquids with intact phytochemical integrity.
Commercial Pilot Specs
Acute, sub-chronic, Ames genotoxicity, and safety pharmacology data packages conforming to global compendia.
Order Toxicology BriefFrom empirical formulation to molecular-level pharmacological elucidation: How contemporary Chinese contract laboratories are bridging centuries of Traditional Chinese Medicine (TCM) with modern biopharma rigor.
Historically, botanical therapeutics faced scrutiny due to variable batch yields and complex botanical matrix interferences. Modern Chinese R&D laboratories deploy ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/MS).
Moving beyond crude extraction, state-of-the-art facilities leverage microfluidic organ-on-a-chip architectures and robotic liquid handlers to screen thousands of fractions within days. This provides deterministic early safety signals and target validation.
Bridging Chinese Pharmacopoeia (ChP) with the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). Analytical protocols are validated under ICH Q2(R1) parameters to facilitate international registration dossiers.
Global pharmaceutical directors, nutraceutical brand formulators, and specialized cosmetic purchasers operate in an era of tightened regulatory oversight. Sourcing laboratory services requires deep audits of scientific competence and reproducibility.
| Evaluation Parameter | Traditional Sourcing Vulnerabilities | State-of-the-Art Laboratory Standard (MedGence / China 4.0) | Commercial Impact for Buyer |
|---|---|---|---|
| Botanical Chemotype Identification | Morphological inspection only; risk of adulteration with sibling species. | Genomic barcoding (ITS2, psbA-trnH) + HPTLC chemical fingerprint matching. | Complete protection against counterfeit ingredients and regulatory recalls. |
| Potency Consistency | Unmonitored seasonal variance causing ±40% variance in active payload. | Geo-spatial and seasonal potency mapping across 12 climatic agro-zones. | Standardized raw material procurement cost drops by 22% on annual contracts. |
| Trace Contaminant Profiling | Occasional heavy metal testing; missing pesticide/aflatoxin multi-residue panels. | GC-MS/MS & LC-MS/MS screening for 500+ pesticides, pyrrolizidine alkaloids, and mycotoxins. | Immediate clearance through FDA Import Alert screenings and EU border controls. |
| Tech-Transfer to Scale-Up | Disconnection between benchtop discovery and commercial plant engineering. | Integrated CRO+CDMO: In-house pilot facilities transitioning directly to commercial batches. | Time-to-market condensed from 24 months down to 8–11 months. |
| Intellectual Property & Data Integrity | Unsecured manual lab notebooks; unclear patent assignment frameworks. | Strict contract research under non-disclosure; proprietary data siloed under 21 CFR Part 11 LIMS. | Total client IP ownership with zero third-party disclosure or formulation leaks. |
How the integration of cyber-physical production networks, robotic analytical stations, and Hunan’s localized botanical industrial clusters provide unmatched cost-to-potency velocity.
Continuous counter-current extraction systems with digital PID temperature, flow, and vacuum control preserve thermally labile botanical phytochemicals with high yield efficiency.
Computerized industrial adsorption and desorption chromatography columns isolate single target glycosides or triterpenes to purities surpassing 98.5% without hazardous chlorinated solvents.
Eco-engineered solvent recovery infrastructure maintains over 95% closed-loop recovery of volatile alcohols, lowering operational overhead while exceeding stringent ESG mandates.
Positioned within Changsha’s high-tech biopharma corridor, our facilities tap into major botanical raw material production corridors (Hunan, Yunnan, Guizhou, Sichuan) in real time.
A transparent, milestone-gated operational journey designed to de-risk investment and provide audit-ready documentation at every phase of pharmaceutical and nutraceutical lifecycle development.
Target molecule identification utilizing proprietary botanical phytochemical databases. Comparative evaluation of plant parts, harvest cycles, and geographic chemotypes.
Deliverable: Sourcing Chemotype DossierEstablishment of HPLC-DAD, LC-MS/MS, and HPTLC testing standards. Complete validation of specificity, linearity, precision, repeatability, and robustness under ICH Q2(R1).
Deliverable: Validated Testing ProtocolBench-to-pilot scale-up optimization. Tuning extraction solvents, solid-liquid ratios, temperature curves, resin profiles, spray-drying, and freeze-drying yield parameters.
Deliverable: Master Batch Record (MBR)GLP-aligned toxicology packages including acute toxicity (LD50), 28/90-day sub-chronic repeated oral dosing, Ames bacterial reverse mutation, and in vitro micronucleus testing.
Deliverable: Preclinical Safety PackageValidated murine and rodent efficacy models followed by GCP-compliant human clinical trials (small-group supplement efficacy trials or Phase I–IV clinical investigations for IND/NDA).
Deliverable: Biostatistical Clinical Study ReportFinal formulation into oral liquids, tablets, delayed-release hard capsules, softgels, or water-dispersible granules under cGMP manufacturing with rigorous QA batch release.
Deliverable: Commercial cGMP Supply BatchesReview how leading healthcare and scientific enterprises utilize our laboratory infrastructure to solve formulation bottlenecks, overcome regulatory hurdles, and achieve market dominance.
Challenge: A US brand faced inconsistent active polyphenol levels and recurring heavy metal rejections in imported raw extracts, stalling a national retail launch.
Lab Execution: MedGence conducted multi-seasonal origin screening, established an HPLC-DAD assay, and engineered an automated water-extraction technique.
Result: Achieved 99.4% batch consistency, zero lead/arsenic trace flags, and secured rapid US FDA GRAS self-affirmation.
Challenge: An EU luxury skincare laboratory sought a clean-label botanical active to replace synthetic retinol without triggering irritation or skin flaking.
Lab Execution: Screened 16 plant fractions via in vitro human dermal fibroblast collagen-synthesis assays and reconstructed 3D epidermis models.
Result: Patented a standardized triterpene saponin fraction with equal efficacy to retinol and zero dermal irritation indices.
Challenge: An innovative pharmaceutical manufacturer needed comprehensive preclinical pharmacology and GLP safety packages for an orphan respiratory drug candidate.
Lab Execution: Conducted 90-day sub-chronic rodent studies, pharmacokinetic tissue distribution, and Phase I escalation trial protocols.
Result: Successfully filed an Investigational New Drug (IND) dossier accepted by national regulatory bodies with zero defect questions.
Our laboratory and CDMO pilot systems have successfully completed contract evaluations and manufacturing campaigns for over 100 enterprise pharmaceutical groups and tertiary medical institutions.
Direct, unedited technical guidance addressing the regulatory, scientific, and contractual expectations of international enterprise procurement teams.
Connect with our senior scientific team to schedule feasibility reviews, request formal validation specifications, or commission sample testing batches.
Pharmacokinetic profiles, tissue distribution, and validated in vivo efficacy models for global regulatory applications.
Request Study Scope
End-to-end human clinical trials covering ethical review, patient recruitment, monitoring, and statistical reporting.
Consult Clinical Lead
Geo-spatial and seasonal fingerprinting optimizing raw material purchasing strategies and active yield consistency.
Download Sourcing Data
Enzyme and cellular target screening providing rapid go/no-go intelligence for lead botanical candidate optimization.
Order In Vitro Assay
Establishment and full compendial validation of quantitative HPLC, GC, and HPTLC methods with complete validation packs.
Verify Method Protocol
Deep natural compound isolation, structural elucidation, and chromatographic profiling of medicinal plants.
Screen Active Library
Full-scale cGMP manufacturing of capsules, tablets, liquids, and granules with strict confidentiality protection.
Request Plant Audit
Definitive toxicology datasets supporting new drug and dietary supplement registration filings worldwide.
Order Safety Protocol